Drozitumab
Drozitumab
Drozitumab (pronounced droh-zih-too-mab) is a type of monoclonal antibody used in the field of oncology to treat certain types of cancer. It is designed to bind to specific proteins found on the surface of cancer cells, thereby inhibiting their growth and proliferation.
Etymology
The name "Drozitumab" is derived from the International Nonproprietary Names (INN), where "-mab" is a suffix for monoclonal antibodies. The prefix "Drozitu-" does not have a specific meaning and is used to create a unique name.
Mechanism of Action
Drozitumab works by binding to the DR5 receptor, a protein found on the surface of many types of cancer cells. This binding triggers a process called apoptosis, or programmed cell death, in the cancer cells. This helps to slow down or stop the growth of the cancer.
Related Terms
- Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- Oncology: The branch of medicine that deals with the prevention, diagnosis, and treatment of cancer.
- DR5 receptor: A protein found on the surface of many types of cancer cells that can trigger apoptosis when bound by certain substances.
- Apoptosis: A process of programmed cell death that occurs in multicellular organisms.
See Also
External links
- Medical encyclopedia article on Drozitumab
- Wikipedia's article - Drozitumab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski